[1]
|
T. J. Walsh, “Trichosporonosis,” Infectious Disease Clinics of North America, Vol. 3, No. 1, 1989, pp. 43-52.
|
[2]
|
K. Shimazu, M. Ando, T. Sakata, K. Yoshida and S. Araki, “Hypersensitivity Pneumonitis Induced by Trichosporon cutaneum,” American Review of Respiratory Disease, Vol. 130, No. 3, 1984, pp. 409-411.
|
[3]
|
S. Kataoka-Nishimura, H. Akiyama, K. Saku, M. Kashiwa, S. Mori, S. Tanikawa, H. Sakamaki and Y. Onozawa, “Invasive Infection Due to Trichosporon cutaneum in Patients with Hematologic Malignancies,” Cancer, Vol. 82, No. 3, 1998, pp. 484-487. http://dx.doi.org/10.1002/(SICI)1097-0142(19980201)82:3<484::AID-CNCR9>3.0.CO;2-P
|
[4]
|
V. Kremery Jr., F. Mateicka, A. Kunova, S. Spanik, J. Gyarfas, Z. Sycova and J. Trupl, “Hematogenous Trichosporonosis in Cancer Patients: Report of 12 Cases Including 5 during Prophylaxis with Itraconazole,” Support Care Cancer, Vol. 7, No. 1, 1999, pp. 39-43. http://dx.doi.org/10.1007/s005200050221
|
[5]
|
D. P. Kontoyiannis, H. A. Torres, M. Chagua, R. Hachem, J. J. Tarrand, G. P. Bodey and I. I. Raad, “Trichosporonosis in a Tertiary Care Cancer Center: Risk Factors, Changing Spectrum and Determinants of Outcome,” Scandinavian Journal of Infectious Disease, Vol. 36, No. 8, 2004, pp. 564-569.
|
[6]
|
C. Girmenia, L. Pagano, B. Martino, D. D’Antonio, R. Fanci, G. Specchia, L. Melillo, M. Buelli, G. Pizzarelli, M. Venditti and P. Martino, “Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: A Retrospective Multicenter Study from Italy and Review of the Literature,” Journal of Clinical Microbiology, Vol. 43, No. 4, 2005, pp. 1818-1828. http://dx.doi.org/10.1128/JCM.43.4.1818-1828.2005
|
[7]
|
K. Suzuki, K. Nakase, T. Kyo, T. Kohara, Y. Sugawara, T. Shibazaki, K. Oka, T. Tsukada and N. Katayama, “Fatal Trichosporon Fungemia in Patients with Hematological Malignancies,” European Journal of Haematology, Vol. 84, No. 5, 2010, pp. 441-447. http://dx.doi.org/10.1111/j.1600-0609.2010.01410.x
|
[8]
|
E. Anaissie, A. Gokaslan, R. Hachem, R. Rubin, G. Griffin, R. Robinson, J. Sobel and G. Bodey, “Azole Therapy for Trichosporonosis: Clinical Evaluation of Eight Patients, Experimental Therapy for Murine Infection, and Review,” Clinical Infectious Disease, Vol. 15, No. 5, 1992, pp. 781-787. http://dx.doi.org/10.1093/clind/15.5.781
|
[9]
|
S. Fournier, W. Pavageau, M. Feuillhade, S. Deplus, A. M. Zagdanski, O. Verola, H. Dombret and J. M. Molina, “Use of Voriconazole to Successfully Treat Disseminated Trichosporon asahii Infection in a Patient with Acute Myeloid Leukemia,” European Journal of Clinical Microbiology & Infectious Disease, Vol. 21, No. 12, 2002, pp. 892-896.
|
[10]
|
R. Falk, D. G. Wolf, M. Shaprio and I. Polacheck, “Multidrug Resistant Trichosporon asahii Isolates Are Susceptible to Voriconazole,” Journal of Clinical Microbiology, Vol. 41, No. 2, 2003, p. 911. http://dx.doi.org/10.1128/JCM.41.2.911.2003
|
[11]
|
I. J. Sud and D. S. Feingold, “Heterogeneity of Action Mechanisms among Antimycotic Imidazoles,” Antimicrobial Agents and Chemotherapy, Vol. 20, No. 1, 1981, pp. 171-174. http://dx.doi.org/10.1128/AAC.20.1.71
|
[12]
|
D. Kobayashi, K. Kondo, N. Uehara, S. Otokozawa, N. Tsuji, A. Yagihashi and N. Watanabe, “Endogenous Reactive Oxygen Species Is an Important Mediator of Miconazole Antifungal Effect,” Antimicrobial Agents and Chemotherapy, Vol. 46, No. 10, 2002, pp. 3113-3117. http://dx.doi.org/10.1128/AAC.46.10.3113-3117.2002
|
[13]
|
National Committee for Clinical Laboratory Standards, “Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; Approved Standard,” NCCLS document M27-A, National Committee for Clinical Laboratory Standards, Wayne, 1997.
|
[14]
|
K. Perparim, H. Nagai, A. Hashimoto, Y. Goto, T. Tashiro and M. Nasu, “In Vitro Susceptibility of Trichosporon beigelii to Antifungal Agents,” Journal of Chemotherapy, Vol. 8, No. 6, 1996, pp. 445-448.
|
[15]
|
K. Marr, “Combination Antifungal Therapy: Where Are We Now, and Where Are We Going?” Oncology (Williston Park), Vol. 18, No. 13, 2004, pp. 24-29.
|
[16]
|
H. Senati, C. F. Ramos, A. S. Bayer and M. A. Ghannoum, “Combination Therapy with Amphotericin B and Fluconazole against Invasive Candidiasis in NeutropenicMouse and Infective-Endocarditis Rabbit Models,” Antimicrobial Agents and Chemotherapy, Vol. 41, No. 6, 1997, pp. 1345-1348.
|
[17]
|
A. I. Popp, M. H. White, T. Quadri, L. Walshe and D. Armastrong, “Amphotericin B with and without Itraconazole for Invasive Aspergillosis: A Three-Year Retrospective Study,” International Journal of Infectious Disease, Vol. 3, No. 3, 1999, pp. 157-160. http://dx.doi.org/10.1016/S1201-9712(99)90038-3
|
[18]
|
T. J. Walsh, G. P. Melcher, M. G. Rinaldi, J. Lecciones, D. A. McGough, P. Kelly, J. Lee, D. Callender, M. Rubin and P. A. Pizzo, “Trichosporon beigeli, an Emerging Pathogen Resistant to Amphotericin B,” Journal of Clinical Microbiology, Vol. 28, No. 7, 1990, pp. 1616-1622.
|
[19]
|
A. L. Colombo, A. C. B. Padovan and G. M. Chaves, “Current Knowledge of Trichosporon spp. and Trichosporonosis,” Clinical Microbiology Reviews, Vol. 24, No. 4, 2011, pp. 682-700. http://dx.doi.org/10.1128/CMR.00003-11
|